AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05168748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMJ995 single agent
Description: Single intravenous administration of IMJ995
Study NCT06474975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AURA 10 PET/CT
Description: The PET/CT specimen imager (AURA 10 PET/CT) is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard
Study NCT05425069 — intervention group
Intervention type: DRUG
Intervention: Comparison MoCA test and EEG connectivity pre, intra and postoperative between groups P vs D-P
Description: We compare de impact in EEG, anesthetic condition, and recovery EEG and cognitive clinical characteristic with MoCA test between both groups (propofol vs propofol dexmedetomidine)
Study NCT05740033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split-Thickness Skin Graft for Radial Forearm Donor Site Closure
Description: This method is performed by harvesting a 0.014-inch skin graft harvested from the anterolateral thigh on the side of the RFFF to reconstruct the forearm donor site. This skin graft is then used to cover the donor defect. The skin graft is sutured in place with 4-0 chromic suture, and a standard bolster dressing will be applied, and a partial splint will be left in place for five days post-operation.
Study NCT05740033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hatchet Flap for Radial Forearm Donor Site Closure
Description: The hatchet flap closures will be performed based on prior description by Lane et al. (12), except no drain is placed in situ. A back cut of 3 to 4 cm is made to aid closure (Figure 1). Tension will be minimized by maintaining the wrist in flexion. A mepore dressing will be applied to the donor site post-operatively for two days.
Study NCT06502106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condensed Internet delivered prolonged exposure (CIPE)
Description: Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
Study NCT06393582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accuracy of full-arch implant impressions
Description: Conventional impressions for full-arch implant impressions will be digitized and used as a reference for comparison.
Study NCT06393582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accuracy of full-arch implant impressions using intraoral scanners
Description: Digital scanners impressions for full-arch implant impressions will be compared to the reference (conventional) impressions
Study NCT05551767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)
Study NCT04568759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global postural re-education
Description: GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
Study NCT04568759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global postural re-education
Description: GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
Study NCT05690282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Pain Management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)
Description: Multimodal Pain Management to minimize patients' reliance on opioids.
Study NCT05615051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface decontamination procedure aiming at reconstructive therapy
Description: Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis
Study NCT05615051 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surface decontamination procedure aiming at reconstructive therapy
Description: Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis
Study NCT06257771 — intervention group
Intervention type: DRUG
Intervention: Alcohol (Ethanol)
Description: Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.
Study NCT05492695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galcanezumab
Description: Galcanezumab is a calcitonin-gene related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
Study NCT05492695 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Galcanezumab' placebo. This is the same vehicle as the study intervention formulation but does not contain active galcanezumab-gnlm.
Study NCT04680442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.
Study NCT04680442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.
Study NCT04680442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
Study NCT04680442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
Study NCT04680442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab emtansine
Description: Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.
Study NCT04680442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.
Study NCT06518603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 20mg/kg/day
Description: Caffeine citrate 20mg/kg/day given orally once daily for 28 days
Study NCT06518603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Sterile water 1ml/kg/day
Description: Placebo-sterile water 1mg/kg/day given orally once daily for 28 days
Study NCT04505865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction
Description: The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~1) Elicitation of the Relaxation Response through mind-body techniques; 2) discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and 3) coping strategies and adaptive perspective-taking to promote positive well-being.
Study NCT04174755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product
Description: Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
Study NCT04174755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Diet and exercise advice for 40 weeks
Study NCT04174755 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care
Description: Diet and exercise advice for 40 weeks
Study NCT06506266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFA-152a
Description: HFA-152a is administered via oral inhalation
Study NCT04539795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study NCT06506266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFA-134a
Description: HFA-134a is administered via oral inhalation
Study NCT06506266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiolabeled saline solution
Description: Radiolabeled saline solution is administered via oral inhalation
Study NCT06093815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection
Description: A pre specified amount will be injected in tissue at selected timepoints
Study NCT06585488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-53038
Description: Administered orally
Study NCT06585488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered by intravenous infusion
Study NCT06585488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: administered by intravenous infusion
Study NCT05714956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Online (eMB)
Description: This study's intervention is called Mothers and Babies Online or eMB, which consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention.
Study NCT06375733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH009
Description: administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.
Study NCT06375733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: administered at 160mg BID oral; 28-day a cycle until disease progresses.
Study NCT06375733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH009
Description: the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.
Study NCT04784715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Administered by intravenous infusion
Study NCT04784715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by intravenous infusion
Study NCT04784715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
Study NCT04784715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Administered by intravenous infusion
Study NCT04784715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Administered by intravenous infusion
Study NCT04784715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Administered by intravenous infusion
Study NCT05051150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin 0.03
Description: epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
Study NCT05051150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin 0.05
Description: epinephrine infusion rate of 0.05 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
Study NCT05051150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin 0.07
Description: epinephrine infusion rate of 0.07 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
Study NCT05018260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Feedback according to participants' viewing patterns, in order to modify their attention bias to threat
Study NCT05018260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control
Description: Feedback according to participants' viewing patterns, in order to strengthen their attention control
Study NCT04672265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother tongue and Norwegian
Description: The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.
Study NCT05163470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early on filed functional rehabilitation
Description: Intervention 1 ,called ''On FI.RE. framework '' included a on filed functional rehabilitation framework ,with early return of the player on the field activities during injury recovery. Involve a specific 5 stages framework of functional rehabilitation on filed. Criteria of inclusion and exclusion for each stage are included based on pain, oedema and range of motion specific to nature of injury . Additional included a daily session planning framework for on field functional rehabilitation with a content ,duration and the description of each content.
Study NCT05163470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional on filed functional rehabilitation
Description: Intervention 2 ,called 'traditional rehabilitation' include a on field functional rehabilitation framework ,as the late phase of injury recovery .The framework described as a 5 stages on filed rehabilitation framework based on load monitoring usingGlobal positioning system.No criteria for the player to return to activity on the field cited ,but referred criteria for progression in each stage based on Strength/power depending of the nature of injury.
Study NCT04993794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XueBiJing Injection
Description: XueBiJing, specification 10mL/ampule, packaging 10 ampules/container, concentration 0.1g/mL, were manufactured by a Good Manufacturing Practice certified company in China (Tianjin Chase Sun Pharmaceutical Co., Tianjin, China; China lot number 1304291, 1401091 and, 1501261). Generally, the treatment duration of the study was at least 5 days.
Study NCT04993794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Same saline dose as XueBiJing injection is taken intravenously.
Study NCT05741281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercises program
Description: - Physical exercise program is an innovative exercise program-consisting of three basic parts (warm up - physical fitness - cool down). It was developed previously by the researcher under the supervision of experienced trainer of physical exercise. The session will begin with a 5- to 10-minutes warm-up consisting of stretching and bending movements. This will be followed by physical fitness phase for 30 to 35 minutes which consist of rapid walking accompanied by a variety of arm and leg movements. The session will be ended by a 5- to 10-minutes cool down phase similar to the warm-up. The total time needed for finishing the physical exercise intervention will be approximately 1 hour.
Study NCT05741281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercises program
Description: - Physical exercise program is an innovative exercise program-consisting of three basic parts (warm up - physical fitness - cool down). It was developed previously by the researcher under the supervision of experienced trainer of physical exercise. The session will begin with a 5- to 10-minutes warm-up consisting of stretching and bending movements. This will be followed by physical fitness phase for 30 to 35 minutes which consist of rapid walking accompanied by a variety of arm and leg movements. The session will be ended by a 5- to 10-minutes cool down phase similar to the warm-up. The total time needed for finishing the physical exercise intervention will be approximately 1 hour.
Study NCT05529056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 01
Description: Atropine sulfate 01 ophthalmic solution
Study NCT05529056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 02
Description: Atropine sulfate 02 ophthalmic solution
Study NCT05529056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 03
Description: Atropine sulfate 03 ophthalmic solution
Study NCT05529056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ophthalmic solution
Study NCT06442865 — intervention group
Intervention type: DEVICE
Intervention: AMNIODERM+
Description: A common surgical approach in chronic wound treatment aims at the promotion of epithelization by a combination of debridement manipulations (removal of non-vital tissues) and infection/inflammation management using antibacterial wound dressings (antibiotics or silver covering). The advantages of biomaterials can be attributed to their unique mechanical, immunological, and regenerative properties.~The product will be evaluated in the subjects not responding to SoC.
Study NCT05100706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (CACB)
Description: Ropivacaine 0.2% infusion through adductor canal catheter
Study NCT05100706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham continuous adductor canal block (ShACB).
Description: NaCl 0.9% infusion through adductor canal catheter
Study NCT05932342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated program of cognitive remediation, physical exercise and socially stimulating activity
Description: Cognitive Remediation (CR) is a well-established intervention that aims to improve neurocognitive abilities (such as memory performance, executive functioning, processing speed, and attention) using four techniques: didactic teaching, computerized drills, in-class strategic monitoring and discussions of the generalization of cognitive skills to daily life.~The physical exercise component consists of physical activities designed for the geriatric population that aim to reduce sedentary behaviors while increasing social engagement.~The socially stimulating activity aim to decrease social isolation, improve well-being, community connection and rapport.
Study NCT06736574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil (OM)
Description: Oral Tablet
Study NCT06736574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT06735482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic play program
Description: Therapeutic Play programs include activities that address core strength, bilateral coordination, motor skills, visual skills, body awareness, outdoor sensory activities, vestibular, and balance skills.
Study NCT06735196 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: sampling capsule endoscopy
Description: Healthy volunteers swallowed SCEs to collect intestinal fluids in different intestinal areas. When SCEs excreted, the fluids inside SCEs would be collected for microbiome and metabolome analysis.
Study NCT06736444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia (BBTI)
Description: Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
Study NCT06736444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Behavioral Therapy for Insomnia (BBTI)
Description: Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
Study NCT06736444 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Alcohol Screening and Intervention for College Students (BASICS)
Description: Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.